Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 129,600 shares of the company’s common stock with a per share exercise price of $24.12, the closing trading price on the grant date, and 64,800 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
